{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:11:51Z","timestamp":1781629911991,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human immunodeficiency virus (HIV) is a rare cause of thrombotic microangiopathies (TMA), that can present either with normal ADAMTS13 activity (referred as HIV-related TMA) or suppressed ADAMTS13 activity (referred as HIV-related acquired thrombotic thrombocytopenic purpura, aTTP). The distinct characteristics and management of these two conditions is poorly known, given their rarity and often overlapping features. Here, we report the case of a 46-year-old female patient with TTP who received a diagnosis of HIV infection at her ADAMTS13 relapse and obtained complete remission only with antiretroviral therapy (ART). Moreover, we summarize the existing evidence in the literature about clinical presentation, outcomes and treatment of HIV-related aTTP\/TMA.<\/jats:p>","DOI":"10.1007\/s00277-026-06733-7","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:28:44Z","timestamp":1768879724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired thrombotic thrombocytopenic purpura and HIV infection: a case report and review of the literature"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7627-0479","authenticated-orcid":false,"given":"Silvio","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Liparoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri Alessandro","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Artoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Muscatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"4","key":"6733_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","volume":"203","author":"M Scully","year":"2023","unstructured":"Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R et al (2023) A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol 203(4):546\u201363. https:\/\/doi.org\/10.1111\/bjh.19026","journal-title":"Br J Haematol"},{"issue":"6","key":"6733_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17474086.2019.1611423","volume":"12","author":"BS Joly","year":"2019","unstructured":"Joly BS, Coppo P, Veyradier A (2019) An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 12(6):383\u2013395. https:\/\/doi.org\/10.1080\/17474086.2019.1611423","journal-title":"Expert Rev Hematol"},{"key":"6733_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/hematolrep14030035","volume":"14","author":"H Chaudhary","year":"2022","unstructured":"Chaudhary H, Nasir U, Syed K, Labra M, Reggio C, Aziz A, Shah P, Reddy R, Sangha N (2022) COVID-19-associated thrombotic thrombocytopenic purpura: a case report and systematic review. Hematol Rep 14:253\u2013260. https:\/\/doi.org\/10.3390\/hematolrep14030035","journal-title":"Hematol Rep"},{"issue":"14","key":"6733_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN et al (2021) Redefining outcomes in immune TTP: an international working group consensus report. Blood 137(14):1855\u201361. https:\/\/doi.org\/10.1182\/blood.2020009150","journal-title":"Blood"},{"issue":"5","key":"6733_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.revmed.2011.11.015","volume":"33","author":"L Gilardin","year":"2012","unstructured":"Gilardin L, Malak S, Schoindre Y, Galicier L, Veyradier A, Coppo P (2012) Purpura thrombotique thrombocytop\u00e9nique et Autres syndromes de microangiopathie thrombotique Au cours de l\u2019infection par Le virus de l\u2019immunod\u00e9ficience Humaine [Human immunodeficiency virus-associated thrombotic microangiopathies]. Rev Med Interne 33(5):259\u2013264. https:\/\/doi.org\/10.1016\/j.revmed.2011.11.015. French","journal-title":"Rev Med Interne"},{"issue":"10","key":"6733_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/hiv.13305","volume":"23","author":"S Louw","year":"2022","unstructured":"Louw S, Jacobson BF, Wiggill TM, Chapanduka Z, Mayne ES (2022) HIV-associated thrombotic thrombocytopenic purpura (HIV-TTP): a practical guide and review of the literature. HIV Med 23(10):1033\u20131040. https:\/\/doi.org\/10.1111\/hiv.13305","journal-title":"HIV Med"},{"key":"6733_CR7","doi-asserted-by":"publisher","unstructured":"Simon D, Leclercq M, Joly B et al (2024) Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.285391","DOI":"10.3324\/haematol.2024.285391"},{"key":"6733_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12959-018-0189-x","volume":"16","author":"S Louw","year":"2018","unstructured":"Louw S, Gounden R, Mayne ES (2018) Thrombotic thrombocytopenic purpura (TTP)-like syndrome in the HIV era. Thromb J 16:35. https:\/\/doi.org\/10.1186\/s12959-018-0189-x","journal-title":"Thromb J"},{"issue":"4","key":"6733_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, HERCULES Investigators et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380(4):335\u201346. https:\/\/doi.org\/10.1056\/nejmoa1806311","journal-title":"N Engl J Med"},{"issue":"6","key":"6733_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/nejmoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Kn\u00f6bl P, Wu H et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511\u201322. https:\/\/doi.org\/10.1056\/nejmoa1505533","journal-title":"N Engl J Med"},{"key":"6733_CR11","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.eclinm.2025.103168","volume":"82","author":"P Coppo","year":"2024","unstructured":"Coppo P et al (2024) Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (The Capla 1000\u2009+\u2009project). eClinicalMedicine 82:103168. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103168","journal-title":"eClinicalMedicine"},{"key":"6733_CR12","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.blre.2022.100945","volume":"55","author":"M Subhan","year":"2022","unstructured":"Subhan M, Scully M (2022) Advances in the management of TTP. Blood Rev 55:100945. https:\/\/doi.org\/10.1016\/j.blre.2022.100945","journal-title":"Blood Rev"},{"issue":"Suppl 1","key":"6733_CR13","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey S, Vyas GN (2012) Adverse effects of plasma transfusion. Transfusion 52(Suppl 1):65S\u201379S. https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03663.x","journal-title":"Transfusion"},{"issue":"20","key":"6733_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","volume":"132","author":"M Jestin","year":"2018","unstructured":"Jestin M, Benhamou Y et al (2018) Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 132(20):2143\u201353. https:\/\/doi.org\/10.1182\/blood-2018-04-840090","journal-title":"Blood"},{"issue":"10","key":"6733_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK et al (2020) ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 18(10):2496\u2013502. https:\/\/doi.org\/10.1111\/jth.15010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"6733_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2141.2011.08636.x","volume":"153","author":"D Hart","year":"2011","unstructured":"Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T et al (2011) Human immunodeficiency virus-associated thrombotic thrombocytopenic purpura\u2014favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol 153(4):515\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08636.x","journal-title":"Br J Haematol"},{"key":"6733_CR17","doi-asserted-by":"publisher","unstructured":"Baes D, Nicolazzi P et al (2020) Acquired thrombotic thrombocytopenic purpura in HIV-positive patients successfully treated with caplacizumab: about two cases. Nephrol Dial Transpl 35(Suppl 3). https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0240","DOI":"10.1093\/ndt\/gfaa142.P0240"},{"issue":"9","key":"6733_CR18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/j.1537-2995.2007.01346.x","volume":"47","author":"K Gunther","year":"2007","unstructured":"Gunther K, Garizio D, Nesara P (2007) ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion 47(9):1710\u20131716. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01346.x","journal-title":"Transfusion"},{"issue":"3","key":"6733_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.2004.05325.x","volume":"128","author":"N Novitzky","year":"2005","unstructured":"Novitzky N, Thomson J, Abrahams L, du Toit C, McDonald A (2005) Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 128(3):373\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05325.x","journal-title":"Br J Haematol"},{"issue":"4","key":"6733_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jca.21692","volume":"34","author":"A Masoet","year":"2019","unstructured":"Masoet A, Bassa F, Chothia MY (2019) Hiv-associated thrombotic thrombocytopaenic purpura: a retrospective cohort study during the antiretroviral therapy era. J Clin Apher 34(4):399\u2013406. https:\/\/doi.org\/10.1002\/jca.21692","journal-title":"J Clin Apher"},{"issue":"3","key":"6733_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-3083.2008.02143.x","volume":"68","author":"S Malak","year":"2008","unstructured":"Malak S, Wolf M, Millot GA et al (2008) Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scand J Immunol 68(3):337\u201344. https:\/\/doi.org\/10.1111\/j.1365-3083.2008.02143.x","journal-title":"Scand J Immunol"},{"issue":"1","key":"6733_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jca.21673","volume":"34","author":"L Swart","year":"2019","unstructured":"Swart L, Schapkaitz E, Mahlangu JN (2019) Thrombotic thrombocytopenic purpura: a 5-year tertiary care centre experience. J Clin Apher 34(1):44\u201350. https:\/\/doi.org\/10.1002\/jca.21673","journal-title":"J Clin Apher"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06733-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:49:16Z","timestamp":1781628556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06733-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6733"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06733-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent for the publication of this paper was obtained from the subject involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}